| Added by | mollevi |
|---|---|
| Group name | EquipeMY |
| Item Type | Journal Article |
| Title | ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research |
| Creator | Marchiň et al. |
| Author | C. Marchiň |
| Author | M. Scaltriti |
| Author | M. Ladanyi |
| Author | A. J. Iafrate |
| Author | F. Bibeau |
| Author | M. Dietel |
| Author | J. F. Hechtman |
| Author | T. Troiani |
| Author | F. López-Rios |
| Author | J.-Y. Douillard |
| Author | J. S. Reis-Filho |
| Abstract | BACKGROUND: NTRK1, NTRK2 and NTRK3 fusions are present in a plethora of malignancies across different histologies. These fusions represent the most frequent mechanism of oncogenic activation of these receptor tyrosine kinases, and biomarkers for the use of TRK small molecule inhibitors. Given the varying frequency of NTRK1/2/3 fusions, crucial to the administration of NTRK inhibitors is the development of optimal approaches for the detection of human cancers harbouring activating NTRK1/2/3 fusion genes. MATERIALS AND METHODS: Experts from several Institutions were recruited by the European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group (TR and PM WG) to review the available methods for the detection of NTRK gene fusions, their potential applications, and strategies for the implementation of a rational approach for the detection of NTRK1/2/3 fusion genes in human malignancies. A consensus on the most reasonable strategy to adopt when screening for NTRK fusions in oncologic patients was sought, and further reviewed and approved by the ESMO TR and PM WG and the ESMO leadership. RESULTS: The main techniques employed for NTRK fusion gene detection include immunohistochemistry, fluorescence in situ hybridization (FISH), RT-PCR, and both RNA-based and DNA-based next generation sequencing (NGS). Each technique has advantages and limitations, and the choice of assays for screening and final diagnosis should also take into account the resources and clinical context. CONCLUSION: In tumours where NTRK fusions are highly recurrent, FISH, RT-PCR or RNA-based sequencing panels can be used as confirmatory techniques, whereas in the scenario of testing an unselected population where NTRK1/2/3 fusions are uncommon, either front-line sequencing (preferentially RNA-sequencing) or screening by immunohistochemistry followed by sequencing of positive cases should be pursued. |
| Publication | Annals of Oncology: Official Journal of the European Society for Medical Oncology |
| Volume | 30 |
| Issue | 9 |
| Pages | 1417-1427 |
| Date | 09 01, 2019 |
| Journal Abbr | Ann. Oncol. |
| Language | eng |
| DOI | 10.1093/annonc/mdz204 |
| ISSN | 1569-8041 |
| Library Catalog | PubMed |
| Extra | PMID: 31268127 |
| Tags | Biomarkers, Tumor, fluorescence in situ hybridisation, High-Throughput Nucleotide Sequencing, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Medical Oncology, Membrane Glycoproteins, Neoplasms, next-generation sequencing, NTRK1, NTRK2, NTRK3, Oncogene Proteins, Fusion, Precision Medicine, Protein Kinase Inhibitors, Receptor, trkA, Receptor, trkB, Receptor, trkC, Translational Medical Research |
| Date Added | 2020/06/04 - 14:49:00 |
| Date Modified | 2020/06/04 - 14:49:00 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
